Biotech news
Africa
For something to be innovative it must “add value” and companies must ensure they understand the term in order to succeed, the 2016 BIO International Convention has heard. 7 June 2016
Americas
The 2016 BIO International Convention has heard that drug companies are on a mission to discover new tools to support the development of anti-infectives due to a decrease in the development of new antibiotics. 7 June 2016
Pharma
EPO case law suggests that inventions covering homeopathic medicines do not have to meet a higher bar of patentability than conventional medicaments, but it still must be shown that the claimed products lead to the alleged therapeutic effect. André Guder of Uexküll & Stolberg reports. 7 June 2016
Americas
If you can find the time between attending sessions and networking, making the most of the local area is an essential part of the 2016 BIO International Convention. LSIPR offers five tips for things to see and do in San Francisco. 6 June 2016
Americas
In an interview with LSIPR, Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization, explains more about the big issues affecting it at the moment and how the trade association is responding. 6 June 2016
Biotech
The biotech industry on both sides of the Atlantic is facing serious challenges in protecting its inventions, argues Nathalie Moll, secretary general of EuropaBio, which is organising a discussion on the topic at the 2016 BIO International Convention in San Francisco. 5 June 2016
Biotech
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR. 5 June 2016
Pharma
With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe. 2 June 2016
Americas
In 2015 the US Federal Circuit resolved the biosimilars case of Amgen v Sandoz. But the parties did not stop there, meaning the Supreme Court could potentially review it. LSIPR looks at the consequences of a possible review. 31 May 2016
Americas
Thermo Fisher Scientific has announced that it will buy FEI, an electron microscopy company, for $4.2 billion. 31 May 2016